| Literature DB >> 14643908 |
Nobuo Wakata1, Toyokazu Saito, Sachiko Tanaka, Toshihiko Hirano, Kitaro Oka.
Abstract
Tacrolimus hydrate (FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test (myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14643908 DOI： 10.1016/s0303-8467(03)00046-5
Source DB: PubMed Journal: Clin Neurol Neurosurg ISSN： 0303-8467 Impact factor: 1.876